August 30, 2024 07:01 AM EDT

NuCana stops Phase 2 as chemotherapy derivative 'unlikely' to meet primary endpoint

Katherine Lewin

News Reporter

Chemotherapy biotech NuCana’s stock $NCNA tanked nearly 50% in premarket trading Friday following a Thursday announcement that it had stopped a Phase 2 trial due …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

NuCana stops Phase 2 as chemotherapy derivative 'unlikely' to meet primary endpoint

Katherine Lewin

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Exclusive: A male contraceptive may prevent 99% of pregnancies. Now it’s up to a small biotech to finish testing it

GSK, iTeos rejuvenate struggling TIGIT space with positive Phase 2 Jemperli combo data in lung cancer

Adcomm says Intercept's rare liver disease drug should not get full approval

House passes Biosecure Act, sending Chinese biotech ban to Senate

Post-Hoc: Big promises built Moderna. They might also be its undoing

Nu­Cana stops Phase 2 as chemother­a­py de­riv­a­tive 'un­like­ly' to meet pri­ma­ry end­point

News Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

NuCana stops Phase 2 as chemotherapy derivative 'unlikely' to meet primary endpoint